erenumab (aimovig) is the first of four new migraine drugs in the pipeline that target calcitonin gene-related peptide (cgrp), a molecule that's produced in nerve cells of the.
. "the importance of our new method is that it allows for precise and automated measurement of the disease," bentley added in the study published in the journal radiology..